Apolipoproteins in vascular biology and atherosclerotic disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms without new primary data or systematic search
PubMed 34625741 · doi:10.1038/s41569-021-00613-5
What was done
This narrative review synthesizes the roles of key apolipoproteins (apoB-100, apoB-48, apoA-I, apoC-II, apoC-III, apoE, and apo(a)) in lipoprotein metabolism, vascular biology, atherogenesis, and cardiovascular therapeutic development based on literature summary.
What was found
The abstract reports no empirical numbers or quantitative effect sizes. It describes qualitative biological roles: apoB-100 structures VLDL, IDL, LDL, and Lp(a); apoB-48 forms the backbone of chylomicrons; apoA-I scaffolds HDL for reverse cholesterol transport; apoC-II, apoC-III, and apoE regulate triglyceride-rich lipoproteins; and apo(a) covalently binds apoB-100.
Why it matters
It provides an overview connecting apolipoprotein physiology to atherogenic disease mechanisms and highlights their emerging roles as cardiovascular drug targets.
Limits
This is a narrative review with no primary data, quantitative synthesis, or reported systematic search criteria.
Cited by
- supports ApoB-100 is the structural apolipoprotein that sits on low-density lipoproteins (LDLs), intermediate-density lipoproteins (IDLs), and very-low-density lipoproteins (VLDLs).
- supports ApoB-48 is the structural apolipoprotein that wraps chylomicrons.